The present disclosure provides peptides that inhibit a binding interaction between a β integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, particularly nanoparticle compositions, comprising the same and to methods of using the peptides to treat atherosclerosis, thrombosis, stroke, heart attack, inflammation, acute respiratory distress syndrome (ARDS), autoimmune diseases, AV Fistula for hemodialysis or organ transplantation.

Methods and compositions for treating cancer, including brain cancers such as diffuse intrinsic pontine glioma (DIPG) and glioblastoma (GBM), breast cancers, melanomas, cervical cancers, bladder cancers, lung cancers, neuroblastomas, and rhabdomyosarcomas (RMS), are described. Also described are methods of preparing cells comprising chimeric antigen receptors (CARs), such as CAR T cells, that target integrin alphav beta3 (αvβ3).

The present invention relates to the field of biotechnology, specifically to an isolated alternative intracellular signalling domain of a chimeric antigen receptor (CAR) and to a chimeric antigen receptor (CAR) comprising, said signalling domain. The invention also relates to a nucleic acid coding an alternative intracellular signalling domain of a chimeric antigen receptor, and to a nucleic acid coding a chimeric antigen receptor with the above-mentioned signalling domain, to an expression vector, to a delivery vector, and also a genetically modified cell which comprises the above-mentioned chimeric antigen receptor, and to a method for producing said cell.

The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of integrin αvβ3.The invention also includes drug conjugates comprising said peptides,conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and dmg conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by integrin αvβ3.

The invention discloses a fusion protein, preparation method thereof and use thereof and belongs to the field of biopharmaceutical technology. The fusion protein according to the present invention has anti-tumor, anti-autoimmune diseases and anti-inflammatory functions, and therapeutic effects on ophthalmic diseases. According to the long-acting, multifunctional fusion protein of the present invention, the EDSM-Y or EDSM-X polypeptide is fused to the antibody immunoglobulin Fc fragment by a flexible linker so as to obtain the fusion proteins I-V, which can improve the efficacy, prolong the half-life and enhance stability, have characteristics of strong effect, low toxicity and the like, and can be used for the prevention and treatment of solid tumors and various types of inflammation and neovascular ophthalmic diseases. The fusion protein is expressed in a prokaryotic cell or a eukaryotic cell by a genetic engineering method, and the expressed fusion protein is obtained by affinity chromatography.

A transgenic mouse comprising T30A, S32P, Q33L, N39D, and M470Q mutations in GPIIIa, as well as methods for making the transgenic mouse and methods for using the transgenic mouse to screen test compounds are described.

The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of integrin αvβ3. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by integrin αvβ3.

A transgenic mouse comprising T30A, S32P, Q33L, N39D, and M470Q mutations in GPIIIa, as well as methods for making the transgenic mouse and methods for using the transgenic mouse to screen test compounds are described.

Disclosed herein are compositions and methods for inhibiting collagen production mediated by the Fused in Sarcoma (FUS) ribonucleoprotein. As disclosed herein, the C terminal domain of FUS contains an uncommon nuclear localization sequence (NLS) motif called PY-NLS that binds the nuclear import receptor transportin. Phosphorylation of FUS leads to its association with transportin and nuclear translocation with consequent increased in collagen production. Therefore, disclosed herein is an isolated peptide having a transportin-binding moiety, which inhibits FUS from binding transportin, linked to a membrane translocating motif. These compositions and methods can be used to inhibit FUS-mediated collagen production, and treat fibrotic disease involving FUS-mediated collagen accumulation in kidneys and other organs displaying fibrotic diseases.

In alternative embodiments, provided are products of manufacture, such as assays, chimeric nucleic acids and nucleic acid constructs, recombinant cells, and methods, comprising use of beta3-integrin (ITGB3) promoters operatively linked to a reporter, for drug screening, and in particular, screening for agents that inhibit cancer cell survival and metastasis. In alternative embodiments, compositions and methods as provided herein also can be used to identifying novel pathways that lead to acquired resistance, stemness, and anchorage independent growth; and characterizing distinct populations of cancer cells within a tumor microenvironment.